Analyst Price Target is $3.25
▲ +2,776.11% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for Otonomy in the last 3 months. The average price target is $3.25, with a high forecast of $6.00 and a low forecast of $0.50. The average price target represents a 2,776.11% upside from the last price of $0.11.
Current Consensus is
The current consensus among 3 contributing investment analysts is to hold stock in Otonomy. This rating has held steady since November 2022, when it changed from a Buy consensus rating.
Otonomy, Inc. operates as a biopharmaceutical company. engages in the development of therapeutics for neurotology. The firm's product pipeline includes OTIVIDEX (dexamethasone) Meniere's disease, OTIPRIO (ciprofloxacin otic suspension) acute otitis media with tubes (AOMT), OTO-313 (gacyclidine) tinnitus, OTO-413 (BDNF) hidden hearing Loss, OTO-510 (otoprotectant) prevent CIHL, OTO-6XX (hair cell regeneration) severe hearing loss. It operates under the Otiprio brand. The company was founded by Jay B. Lichter, Jeffrey Harris, Rick Friedman, and Allen F. Ryan on May 6, 2008 and is headquartered in San Diego, CA.